NPCENeuroPace, Inc.
Price
+16%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality strong, a flag to check, growing in the filings, the market against it.
Charts
As reported to the SEC, without any scoring.
NeuroPace, Inc. (NPCE) reported revenue of $23M in Q2 2026 (quarter ended Jun 30, 2026), up 17% from the same quarter a year earlier. That came with a gross margin of 83% and net loss of $6.2M. For the full year FY2025, revenue was $100M (+25% year on year) and net income −$21M. The next results filing is expected around Nov 3, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 11, 2026NeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance.Earnings release · press release
- Jul 28, 2026NeuroPace Receives FDA Guidance on PMA Supplement for Indication Expansion into Idiopathic Generalized.Regulation FD disclosure · press release
- May 12, 2026NeuroPace Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Guidance.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.